Phase I trial and pharmacokinetic study of all-trans-retinoic acid administered on an intermittent schedule in combination with interferon-α2a in pediatric patients with refractory cancer

Journal of Clinical Oncology

Volumn 15, Issue 11, 1997, Pages 3330-3337

  Adamson, Peter C ^a   Reaman, Gregory ^a   Finklestein, Jerry Z ^a   Feusner, James ^a   Berg, Stacey L ^a   Blaney, Susan M ^a   O'Brien, Michelle ^a   Murphy, Robert F ^a   Balis, Frank M ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON A; RETINOIC ACID;

ADOLESCENT; ADULT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER; CANCER CHEMOTHERAPY; CANCER IMMUNOLOGY; CANCER REGRESSION; CHEILITIS; CHILD; CHILDHOOD CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; HEADACHE; HUMAN; MALE; NAUSEA; NEUROTOXICITY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; VOMITING;

EID: 0030678635     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1997.15.11.3330     Document Type: Article

References (44)

1. Smith MA, Parkinson DR, Cheson BD, et al: Retinoids in cancer therapy. J Clin Oncol 10:839-864, 1992
2. Lippman SM, Kessler JF, Meyskens FL: Retinoids as preventive and therapeutic anticancer agents (part II). Cancer Treat Rep 71:391-405, 1987
3. Lippman SM, Kessler JF, Meyskens FL: Retinoids as preventive and therapeutic anticancer agents. Cancer Treat Rep 71:493-515, 1987
4. Sidell N: Retinoic acid induced growth inhibition and morphologic differentiation of human neuroblastoma cells in vitro. J Natl Cancer Inst 68:589-593, 1982
5. Thiele CJ, Reynolds CP, Israel MA: Decreased expression of N-myc precedes retinoic acid-induced morphological differentiation of human neuroblastoma. Nature 313:404-406, 1985
6. Vincent T, Re GG, Hazen-Martin DJ, et al: All-trans-retinoic acid-induced growth suppression of blastemal Wilms' tumor. Pediatr Pathol Lab Med 16:777-789. 1996
7. Thein R, Lotan R: Sensitivity of cultured human osteosarcoma and chondrosarcoma cells to retinoic acid. Cancer Res 42:4771-4775, 1982
8. Song LN: Effects of retinoic acid and dexamethasone on proliferation, differentiation, and glucocorticoid receptor expression in cultured human osteosarcoma cells. Oncol Res 6:111-118, 1994
9. Crouch GD, Helman LJ: All-trans-retinoic acid inhibits the growth of human rhabdomyosarcoma cell lines. Cancer Res 51:4882-4887, 1991
10. Ramp U, Gerharz CD, Eifler E, et al: Effects of retinoic acid metabolites on proliferation and differentiation of the clonal rhabdomyosarcoma cell line BA-HAN-1C. Biol Cell 81:31-37, 1994
11. Adamson PC: All-trans-retinoic acid pharmacology and its impact on the treatment of acute promyelocytic leukemia. Oncologist 1:305-314, 1996
12. Muindi J, Frankel SR, Miller WH Jr, et al: Continuous treatment with all-trans retinoic acid causes a progressive reduction in plasma drug concentrations: Implications for relapse and retinoid "resistance" in patients with acute promyelocytic leukemia. Blood 79:299-303, 1992
13. Smith MA, Adamson PC, Balis FM, et al: Phase I and pharmacokinetic evaluation of all-trans-retinoic acid in pediatric patients with cancer. J Clin Oncol 10:1666-1673, 1992
14. Muindi J, Frankel SR, Huselton C, et al: Clinical pharmacology of oral all-trans retinoic acid in patients with acute promyelocytic leukemia. Cancer Res 52:2138-2142, 1992
15. Adamson PC, Bailey J, Pluda J, et al: Pharmacokinetics of all-trans-retinoic acid administered on an intermittent schedule. J Clin Oncol 13:1238-1241, 1995
16. Warrell RP, Jr.: Retinoid resistance in acute promyelocytic leukemia: New mechanisms, strategies, and implications. Blood 82:1949-1953, 1993
17. Fenaux P: The role of all-trans-retinoic acid in the treatment of acute promyelocytic leukemia. Acta Haematol 1:22-27, 1993
18. Adamson PC, Balis FM, Smith MA, et al: Dose dependent pharmacokinetics of all-trans-retinoic acid. J Natl Cancer Inst 84:1332-1335, 1992
19. Adamson PC, Boylan JF, Balis FM, et al: Time course of induction of metabolism of all-trans-retinoic acid and the up-regulation of cellular retinoic acid-binding protein. Cancer Res 53:472-476, 1993
20. Wadler S, Schwartz EL: Antineoplastic activity of the combination of interferon and cytotoxic agents against experimental and human malignancies: A review. Cancer Res 50:3473-3486, 1990
21. Goldstein D, Laszlo J: The role of interferon in cancer therapy: A current perspective. Ca Cancer J Clin 38:1-20, 1988
22. Ochs J, Abromowitch M, Rudnick S, et al: Phase I-II study of recombinant alpha-2 interferon against advanced leukemia and lymphoma in children. J Clin Oncol 4:883-887, 1986
23. Ochs J, Brecher ML, Mahoney D, et al: Recombinant interferon alfa given before and in combination with standard chemotherapy in children with acute lymphoblastic leukemia in first marrow relapse: A Pediatric Oncology Group pilot study. J Clin Oncol 9:777-782, 1991
24. Dow LW, Raimondi SC, Culbert SJ, et al: Response to alpha-interferon in children with Philadelphia chromosome-positive chronic myelocytic leukemia. Cancer 68:1678-1684, 1991
25. Bollag W: Retinoids and interferon: A new promising combination: Br J Haematol 79:87-91, 1991
26. Frey JR, Peck R, Bollag W: Antiproliferative activity of retinoids, interferon alpha and their combination in five human transformed cell lines. Cancer Lett 57:223-227, 1991
27. Gallagher RE, Lurie KJ, Leavitt RD, et al: Effects of interferon and retinoic acid on the growth and differentiation of clonogenic leukemia cells from acute myelogenous leukemia patients treated with recombinant leukocyte-αA interferon. Leuk Res 11:609-619, 1987
28. Higuchi T, Hannigan GE, Malkin D, et al: Enhancement by retinoic acid and dibutyryl cyclic adenosine 3′:5′-monophosphate of the differentiation and gene expression of human neuroblastoma cells induced by interferon. Cancer Res 51:3958-3964, 1991
29. Rosolen A, Colamonici OR, Pfeffer LM, et al: Detection of functional interferon alpha receptors in human neuroendocrine tumor cell lines using a new monoclonal antibody. Eur Cytokine Netw 3:81-88, 1992
30. Lippman SM, Parkinson DR, Itri LM, et al: 13-cis-Retinoic acid and interferon alpha-2a: Effective combination therapy for advanced squamous cell carcinoma of the skin. J Natl Cancer Inst 84:235-241, 1992
31. Lippman SM, Kavanagh JJ, Paredes EM, et al: 13-cis-Retinoic acid plus interferon alpha-2a: Highly active systemic therapy for squamous cell carcinoma of the cervix. J Natl Cancer Inst 84:241-245, 1992
32. Guidelines for reporting adverse drug reactions, in Cancer Therapy Evaluation Program Division of Cancer Treatment (ed): National Cancer Institute: Investigator's Handbook. Bethesda, MD, United States Department of Health and Human Services, Public Health Service, National Institutes of Health, 1993, Appendix XII
33. Gibaldi M, Perrier D: Pharmacokinetics (ed 2). New York, NY, Dekker, 1982
34. Towbin R, Gruppo RA: Pulmonary metastases in neuroblastoma. AJR 138:75-78, 1982
35. Thiele CJ, Deutsch LA, Israel MA: The expression of multiple proto-oncogenes is differentially regulated during retinoic acid induced maturation of human neuroblastoma cell lines. Oncogene 3:281-288, 1988
36. Kaplan DR, Matsumoto K, Lucarelli E, et al: Induction of TrkB by retinoic acid mediates biologic responsiveness to BDNF and differentiation of human neuroblastoma cells. Neuron 11:321-331, 1993
37. Lucarelli E, Kaplan DR, Thiele CJ: Selective regulation of TrkA and TrkB receptors by retinoic acid and interferon-gamma in human neuroblastoma cell lines. J Biol Chem 270:24725-24731, 1995
38. Renton KW, Mannering GJ: Depression of hepatic cytochrome P-450-dependent monooxygenase systems with administered interferon inducing agents. Biochem Biophys Res Commun 73:343-348, 1976
39. Sonnenfeld G, Harned CL, Nerland DE: Effects of interferon on drug metabolism. J Biol Response Mod 3:15-18, 1984
40. Wadler S, Schwartz EL, Haynes H, et al: All-trans retinoic acid and interferon-alpha-2a in patients with metastatic or recurrent carcinoma of the uterine cervix: Clinical and pharmacokinetic studies. New York Gynecologic Oncology Group. Cancer 79:1574-1580, 1997
41. Conley BA, Egorin MJ, Sridhara R, et al: Phase I clinical trial of all-trans-retinoic acid with correlation of its pharmacokinetics and pharmacodynamics. Cancer Chemother Pharmacol 39:291-299, 1997
42. Lee JS, Newman RA, Lippman SM, et al: Phase I evaluation of all-trans-retinoic acid in adults with solid tumors. J Clin Oncol 11:959-966, 1993
43. Lee JS, Newman RA, Lippman SM, et al: Phase I evaluation of all-trans retinoic acid with and without ketoconazole in adults with solid tumors. J Clin Oncol 13:1501-1508, 1995
44. Finklestein JZ, Krailo MD, Lenarsky C, et al: 13-cis-Retinoic acid (NSC 122758) in the treatment of children with metastatic neuroblastoma unresponsive to conventional chemotherapy: Report from the Childrens Cancer Study Group. Med Pediatr Oncol 20:307-311, 1992